{"disease":{"id":"refractory-chronic-cough","name":"Refractory chronic cough","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"gefapixant-citrate","indication_name":"Refractory chronic cough","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyfnua","generic_name":"GEFAPIXANT CITRATE","company_name":"Msd K.K.","drug_phase":"marketed","molecular_target":"P2X purinoceptor 3","drug_class":"","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05600777","title":"A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":975,"lead_sponsor_name":"Bellus Health Inc. - a GSK company","has_results":false},{"nct_id":"NCT05599191","title":"A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":825,"lead_sponsor_name":"Bellus Health Inc. - a GSK company","has_results":false},{"nct_id":"NCT06504446","title":"Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":455,"lead_sponsor_name":"Nocion Therapeutics","has_results":false},{"nct_id":"NCT04562155","title":"Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04678206","title":"Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Bellus Health Inc. - a GSK company","has_results":false},{"nct_id":"NCT02612610","title":"A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT03282591","title":"Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT07483489","title":"A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","has_results":false},{"nct_id":"NCT04882943","title":"COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database","phase":"","overall_status":"TERMINATED","enrollment_count":178,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06960759","title":"Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":135,"lead_sponsor_name":"University of Montana","has_results":false},{"nct_id":"NCT05265871","title":"ATP Level and Cough Sensitivity to ATP in Subjects With Refractory/Unexplained Chronic Cough","phase":"","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Kefang Lai","has_results":true},{"nct_id":"NCT07288528","title":"A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":124,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT05733533","title":"A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Guangdong Hengrui Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03662269","title":"Indomethacin for Refractory Chronic Cough","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":84,"lead_sponsor_name":"The First Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05962151","title":"Refractory Chronic Cough Improvement Via NAL ER (RIVER)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Trevi Therapeutics","has_results":true},{"nct_id":"NCT06706765","title":"Group Telehealth Behavioral Cough Suppression Therapy","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Montana","has_results":false},{"nct_id":"NCT02349425","title":"A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02397460","title":"Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT05660850","title":"A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT04454424","title":"Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04265781","title":"Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02476890","title":"Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04471337","title":"Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05628740","title":"Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Nocion Therapeutics","has_results":false},{"nct_id":"NCT02612623","title":"An 8-Week Refractory Chronic Cough Study (MK-7264-021)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04487431","title":"A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Bayer","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}